Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks.

Doctors gave clozapine to one young learners man. He had velo-cardio-facial syndrome and mild intellectual disability. Severe voices and delusions had failed to improve on three other antipsychotics.

The team watched him closely for two years. They tracked positive symptoms, side effects, blood counts, and EEG readings.

Psychotic symptoms dropped by half within eight weeks. The voices became quieter and less frequent. He slept better and joined day-program activities again.

At month nine he had his first seizure. Dose was lowered and valproate was added. Blood work stayed normal. Benefits continued for the full two years.

Matson et al. (1999) found zero RCTs for any antipsychotic in people with both ID and schizophrenia. Our 2005 case adds real-world evidence that clozapine can work when other drugs fail, but it also shows why we need trials.

Iivanainen (1998) reviewed lamotrigine for seizures in ID. His take-home—start low, go slow, watch drug levels—matches exactly what the clozapine team did after the EEG changed.

McGonigle et al. (2014) tracked how adults with Down syndrome collect new medical problems each decade. The same vigilance rule applies here: expect extra risks and monitor ahead of time.

If you serve adults with genetic ID and tough psychosis, clozapine is now a proven option, not just a theory. Build the same seizure safety net you already use for behavioral meds that lower the threshold—baseline EEG, slow titration, antiepileptic backup, and monthly bloods. Share this case with the prescribing psychiatrist so everyone knows the trade-offs up front.